Clinical trials: Gastric Cancer With Peritoneal Dissemination
Gastric Cancer With Peritoneal Dissemination
An Open Prospective Randomized Clinical Study of the Effectiveness, Tolerability and Safety of a Single Intraperitoneal Use of the Drug "Prospidelong, Powder for the Preparation of a Gel for Topical Use, 1000 mg in Vials, Package No. 1" in Patients With Disseminated Gastric Cancer, Phase I-II
It is planned to conduct an open-label, prospective, randomized clinical study of the efficacy, tolerability and safety of a single intraperitoneal administration of the investigational drug Prospidelong at a dose of 4000 mg…
- Trial name
- ИНТЕЛОН-02 (NCT06232434)
- Testing
- Prospidelong, chemotherapy
- Where
- Belarus
- Volunteers
- 120 people
- Sponsor
- Research Institute for Physical Chemical Problems of the Belarusian State University
Advanced Gastric Cancer, Peritoneal Carcinomatosis
A Phase II Study of Conversion Surgery After IP Paclitaxel With XELOX Chemotherapy in AGC With Peritoneal Dissemination
Advanced gastric cancer combined with peritoneal seeind has dismal prognosis with poor response to systemic chemotherapy and with rapid aggravation of symptoms such as abdominal pain, ileus, and poor nutritional intake.
- Trial name
- NCT04797923
- Testing
- 1. Treatment: IP chemotherapy + Systemic chemotherapy, 2. Response evaluation after 4 cycles of IP + systemic chemotherapy
- Where
- South Korea
- Volunteers
- 43 people
- Sponsor
- Gangnam Severance Hospital
Stomach Neoplasm, Peritoneal Carcinomatosis
Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.
A randomized controlled two-armed phase III trial for gastric cancer patients with peritoneal dissemination. Randomization between gastrectomy + cytoreductive surgery + HIPEC (experimental arm) and palliative systemic…
- Trial name
- PERISCOPEII (NCT03348150)
- Testing
- Cytoreductive surgery + Gastrecomy, Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- Where
- Netherlands
- Volunteers
- 102 people
- Sponsor
- The Netherlands Cancer Institute